Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥6,950 JPY
Change Today +100.00 / 1.46%
Volume 462.9K
2267 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
As of 2:00 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

yakult honsha co ltd (2267) Snapshot

Open
¥6,840
Previous Close
¥6,850
Day High
¥6,970
Day Low
¥6,820
52 Week High
04/9/15 - ¥9,030
52 Week Low
06/13/14 - ¥5,020
Market Cap
1.2T
Average Volume 10 Days
407.7K
EPS TTM
¥151.57
Shares Outstanding
175.9M
EX-Date
09/28/15
P/E TM
45.9x
Dividend
¥30.00
Dividend Yield
0.36%
Current Stock Chart for YAKULT HONSHA CO LTD (2267)

Related News

No related news articles were found.

yakult honsha co ltd (2267) Related Businessweek News

View More BusinessWeek News

yakult honsha co ltd (2267) Details

Yakult Honsha Co., Ltd., a probiotics company, primarily manufactures and sells food and beverage products. It operates through Food and Beverages (Japan), Food and Beverages (The Americas), Food and Beverages (Asia and Oceania), Food and Beverages (Europe), Pharmaceuticals, and Others. The company offers food and beverages products comprising fermented milk drinks, juices, noodles, etc. through its home delivery and retail store channels. It also provides pharmaceutical products, including Elplat, a cancer chemotherapeutic agent for the treatment of colorectal cancer; Levofolinate Yakult, an activated folic acid drug; Gemcitabine Yakult, an antineoplastic antimetabolite; recombinant DNA G-CSF chemotherapy preparation Neu-up; Imatinib yakult, a generic antineoplastic drug; and Campto, an active pharmaceutical ingredient. The company is also developing Elplat for gastric cancer; PR610, a hypoxia activated pro drug; Perifosine, a PI3K/Akt inhibitor; Resminostat, an oral HDAC inhibitor; LIV-2008, which are humanized monoclonal anticancer antibodies; antibody biosimilars; and Zoledronic acid intravenous drip, a generic drug for bone lesions. In addition, it offers cosmetics and skin care products under the Parabio, Revecy, and Revecy White brand names; and BECYCLE Lift Repair Essence, which adds firmness and resilience to the skin, as well as operates and manages the Tokyo Yakult Swallows, a professional baseball team. The company was founded in 1935 and is headquartered in Tokyo, Japan.

Founded in 1935

yakult honsha co ltd (2267) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥150.0M
Compensation as of Fiscal Year 2014.

yakult honsha co ltd (2267) Key Developments

Yakult Honsha Co. Ltd. Reports Consolidated and Non Consolidated Earnings Results for the Year Ended March 31, 2015; Provides Consolidated and Non Consolidated Earnings Guidance for the Year Ending March 31, 2016

Yakult Honsha Co. Ltd. reported consolidated and non consolidated earnings results for the year ended March 31, 2015. For the year, the company reported consolidated net sales of JPY 367,980 million compared to JPY 350,322 million a year ago. Operating income was JPY 34,898 million compared to JPY 32,026 million a year ago. Ordinary income was JPY 45,608 million compared to JPY 39,535 million a year ago. Income before income taxes and minority interests was JPY 45,117 million compared to JPY 39,458 million a year ago. Net income was JPY 25,056 million compared to JPY 22,543 million a year ago. Cash flows from operating activities were JPY 55,407 million compared to JPY 48,579 million a year ago. For the year, the company reported non consolidated net sales of JPY 176,391 million compared to JPY 181,826 million a year ago. Operating income was JPY 4,826 million compared to JPY 4,046 million a year ago. Ordinary income was JPY 15,407 million compared to JPY 12,889 million a year ago. Income before income taxes and minority interests was JPY 13,844 million compared to JPY 12,546 million a year ago. Net income was JPY 11,259 million compared to JPY 9,859 million a year ago. The company provided consolidated earnings guidance for the year ending March 31, 2016. For the year, the company expected net sales of JPY 395,000 million, operating income of JPY 39,000 million, ordinary income of JPY 47,500 million and net income of JPY 27,500 million. The company provided non consolidated earnings guidance for the year ending March 31, 2016. For the year, the company expected net sales of JPY 182,500 million, operating income of JPY 5,000 million, ordinary income of JPY 15,500 million and net income of JPY 12,000 million.

Yakult Honsha Co. Ltd. to Report Fiscal Year 2015 Results on May 12, 2015

Yakult Honsha Co. Ltd. announced that they will report fiscal year 2015 results on May 12, 2015

Yakult Honsha Co. Ltd., 2015 Earnings Call, May 12, 2015

Yakult Honsha Co. Ltd., 2015 Earnings Call, May 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2267:JP ¥6,950.00 JPY +100.00

2267 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott India Ltd 3,965 INR -49.75
BioGaia AB kr275.50 SEK -4.00
Biostime International Holdings Ltd $27.55 HKD -4.15
Mead Johnson Nutrition Co $96.96 USD -0.34
View Industry Companies
 

Industry Analysis

2267

Industry Average

Valuation 2267 Industry Range
Price/Earnings 43.7x
Price/Sales 3.0x
Price/Book 3.4x
Price/Cash Flow 46.5x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact YAKULT HONSHA CO LTD, please visit www.yakult.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.